We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ctDNA Could Become an Early Endpoint in Oncology, Says Nonprofit Research Group
ctDNA Could Become an Early Endpoint in Oncology, Says Nonprofit Research Group
The biomarker known as circulating tumor DNA (ctDNA) is well-suited to become an early endpoint in oncology, as it has the potential to improve confidence in the efficacy of novel therapies, thus bringing better treatments to patients faster.